Which elderly patients should be considered for anti-hypertensive treatment? An evidence-based approach

Journal of Human Hypertension

Volumn 12, Issue 9, 1998, Pages 607-613

  Jackson, R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Absolute risk; Cost effectiveness; Elderly; Hypertension treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT;

AGED; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; HYPERTENSION; LIFE EXPECTANCY; MEDICAL DECISION MAKING; PATIENT SELECTION; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; RISK BENEFIT ANALYSIS; UNITED KINGDOM; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 0031686373     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000674     Document Type: Conference Paper

References (16)

1. Sever P et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. Br Med J 1993; 306: 983-987.
2. Subcommittee of WHO/ISH Mild Hypertension Liaison Committee. Summary of the World Health Organisation-International Society of Hypertension guidelines for the management of mild hypertension. Br Med J 1993; 307: 1541-1546.
3. Joint National Committee on Detection Evaluation and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154-183.
4. Core Services Committee. Guidelines for the management of raised blood pressure in New Zealand. Ministry of Health, Wellington, NZ, ISBN 0-477-01740-1, 1995.
5. Jackson R et al. The Management of Raised Blood Pressure in New Zealand. Br Med J 1993; 307: 107-110.
6. MacMahon S et al. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for regression dilution bias. Lancet 1990; 335: 765-774.
7. Collins R et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials. Lancet 1990; 335: 827-838.
8. Insua JT et al. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994; 121: 355-362.
9. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. Br Med J 1995; 310: 452-445.
10. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 cohorts. Lancet 1995; 346: 1647-1653.
11. Mulrow CD et al. Hypertension in the elderly. Implications and generalizability of randomised trials. JAMA 1994; 272: 1932-1938.
12. Alderman MH. Blood pressure management: individualised treatment based on absolute risk and the potential for benefit. Ann Intern Med 1993; 119: 329-335.
13. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of a stroke: a risk profile from the Framingham Study. Stroke 1991; 22: 312-318.
14. Anderson KM, Wilson PWF, Odell PW, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-362.
15. MacMahon S, Rogers A. The effects of antihypertensive treatment on vascular disease: re-appraisal of the evidence in 1993. J Vasc Med Biol 1993; 4: 265-271.
16. Johannesson M, Meltzer D, O'Conor RM. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. Med Decision Making 1997; 17: 382-389.